GSK signs fresh microRNA deal with Regulus Therapeutics for HCV
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics has entered a new collaboration with GlaxoSmithKline (GSK) to develop and commercialise microRNA therapeutics for hepatitis C virus (HCV).